New antibody therapy targets Hard-to-Treat prostate cancer

NCT ID NCT07529717

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Apr 25, 2026 · Last updated May 24, 2026 · Updated 6 times

Summary

This study tests an experimental drug called AZD8359 for men with metastatic prostate cancer that has spread and is no longer responding to standard treatments. The drug is an antibody designed to guide the body's immune cells to attack cancer cells. The trial has two parts: first, finding the safest dose, then testing that dose in more participants to see if it shrinks tumors or lowers PSA levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Orlando, Florida, 32806, United States
Research Site
NOT_YET_RECRUITING

East Brunswick, New Jersey, 08816, United States
Research Site
NOT_YET_RECRUITING

Hackensack, New Jersey, 07601, United States
Research Site
NOT_YET_RECRUITING

Providence, Rhode Island, 02903, United States
Research Site
NOT_YET_RECRUITING

Darlinghurst, 2010, Australia
Research Site
RECRUITING

Melbourne, 3000, Australia
Research Site
NOT_YET_RECRUITING

Seoul, 03722, South Korea
Research Site
RECRUITING

Seoul, 06351, South Korea

Conditions

Explore the condition pages connected to this study.

METASTATIC PROSTATE CANCER